Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Fuyong Du"'
Publikováno v:
TH Open, Vol 07, Iss 02, Pp e97-e104 (2023)
Abstract Background Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177/JNJ-70033093) is an oral small-molecule FXIa inhibi
Externí odkaz:
https://doaj.org/article/62a7421a50364701bd42a20a7eadc061
Autor:
Guozhang Xu, Zhijie Liu, Xinkang Wang, Tianbao Lu, Renee L. DesJarlais, Tho Thieu, Jing Zhang, Zheng Huang Devine, Fuyong Du, Qiu Li, Cynthia M. Milligan, Paul Shaffer, Peder E. Cedervall, John C. Spurlino, Christopher F. Stratton, Beth Pietrak, Lawrence M. Szewczuk, Victoria Wong, Ruth A. Steele, Wouter Bruinzeel, Madhu Chintala, Jose Silva, Michael D. Gaul, Mark J. Macielag, Ravi Nargund
Publikováno v:
Journal of medicinal chemistry. 65(15)
Activated factor XI (FXIa) inhibitors are promising novel anticoagulants with low bleeding risk compared with current anticoagulants. The discovery of potent FXIa inhibitors with good oral bioavailability has been challenging. Herein, we describe our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97b97b82cd74e1de0878b0437d2311e
https://pubmed.ncbi.nlm.nih.gov/35862732
https://pubmed.ncbi.nlm.nih.gov/35862732
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:375-384
JNJ-64179375 (abbreviated as JNJ-9375) is a recombinant human immunoglobin G4 (IgG4) monoclonal antibody engineered to mimic an immunoglobin A (IgA) antibody that was identified in a patient who exhibited markedly prolonged clotting times but without
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d855718c1a965115156f31263d0fbd6b
https://doi.org/10.1124/jpet.119.261032
https://doi.org/10.1124/jpet.119.261032
Autor:
Fuyong Du, Sheng-Ping Wang, Kamal A. Al-Barazanji, Matthew M. Rankin, Andrea R. Nawrocki, Nathaniel H. Wallace, Jianying Liu, Simon A. Hinke, Katharine D'Aquino, George Ho
Publikováno v:
Diabetes. 69
Nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) is highly prevalent in modern societies frequently consuming diets rich in fats and carbohydrates. NASH is characterized by liver steatosis, inflammat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eef5920cd93a97008cf23d053840c6c
https://doi.org/10.2337/db20-1821-p
https://doi.org/10.2337/db20-1821-p
Autor:
Yin Liang, Kenji Arakawa, Kiichiro Ueta, Yasuaki Matsushita, Chiaki Kuriyama, Tonya Martin, Fuyong Du, Yi Liu, June Xu, Bruce Conway, Jamie Conway, David Polidori, Kirk Ways, Keith Demarest
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30555 (2012)
BACKGROUND: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). METHODS: (14)C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing huma
Externí odkaz:
https://doaj.org/article/df414787d96e4b259c141d5ae76d36f9
Autor:
Cuifen Hou, Wall Mark, Zhihua Sui, Keith T. Demarest, Yin Liang, Xuqing Zhang, Jack Kauffman, William V. Murray, Dana L. Johnson, Cailin Chen, Thomas Kirchner, Fuyong Du
Publikováno v:
ACS Medicinal Chemistry Letters. 8:560-565
We have discovered a novel series of tetrahydrobenzimidazoles 3 as TGR5 agonists. Initial structure–activity relationship studies with an assay that measured cAMP levels in murine enteroendocrine cells (STC-1 cells) led to the discovery of potent a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2764d06234e4b20e38d8271ce309e9
https://doi.org/10.1021/acsmedchemlett.7b00116
https://doi.org/10.1021/acsmedchemlett.7b00116
Autor:
Fuyong Du, Brian C. Shook, Karen DiLoreto, Guozhang Xu, Fengbin Song, Yin Liang, Michael David Gaul, Rosie Santulli, Dennis Rentzeperis, Annette Eckardt, Keith T. Demarest, Renee L. DesJarlais
Publikováno v:
Bioorganicmedicinal chemistry letters. 29(20)
Type 2 diabetes mellitus (T2DM) is characterized by chronically elevated plasma glucose levels. The inhibition of glucagon-induced hepatic glucose output via antagonism of the glucagon receptor (GCGR) using a small-molecule antagonist is a promising
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b30b8f1be120fa7a91abbdd01da299a
https://pubmed.ncbi.nlm.nih.gov/31519374
https://pubmed.ncbi.nlm.nih.gov/31519374
Autor:
Fuyong Du, Gee-Hong Kuo, Yin Liang, Guozhang Xu, Michael David Gaul, Keith T. Demarest, June Zhi Xu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 30:127387
(2S,3R,4R,5S,6R)-2-Aryl-5,5-difluoro-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols and (2S,3R,4R,5S,6R)-2-aryl-5-fluoro-5-methyl-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diols were discovered as dual inhibitors of sodium glucose co-transporter prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e14d3ba29a79979b3a7899ecbf00c8b
https://doi.org/10.1016/j.bmcl.2020.127387
https://doi.org/10.1016/j.bmcl.2020.127387
Autor:
Simon A. Hinke, Jose Silva, Guozhang Xu, Michael David Gaul, Seunghun Paul Lee, William V. Murray, Norman D. Huebert, Thomas Kirchner, Gee-Hong Kuo, Fuyong Du, Keith T. Demarest, June Zhi Xu, Yin Liang, Nathaniel H. Wallace
Publikováno v:
Bioorganicmedicinal chemistry letters. 28(21)
A new series of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as dual inhibitors of sodium glucose co-transporter proteins (SGLTs) were disclosed. Two methods were developed to efficiently synthesize C5-fluoro-lacton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3b1facca7dd2a8982bfbb262f059233
https://pubmed.ncbi.nlm.nih.gov/30268701
https://pubmed.ncbi.nlm.nih.gov/30268701
Autor:
Tonya Martin, Fuyong Du, Jenson Qi, Alessandro Pocai, Norquay Lisa, Michael P. Winters, Sanath K. Meegalla, Andrea R. Nawrocki, Mark R. Player, Jianying Liu, Seunghun Paul Lee, Hui Huang, Brian Rady
Publikováno v:
Diabetes. 67
The free fatty acid receptor 1 (FFAR1) mediates fatty acid-induced insulin secretion from pancreatic β-cells. Numerous ligands have been investigated for their antidiabetic actions. The most advanced, fasiglifam (TAK-875), is a site 1 binding agonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::345b41613691f064b747ebcce1dbfa80
https://doi.org/10.2337/db18-609-p
https://doi.org/10.2337/db18-609-p